# Titan International Inc: financial statements, quarterly TWI · NYSE · CIK 899751 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/twi.md) · [Financials](/companies/twi/financials.md) · [Filings](/companies/twi/filings.md) · [Insiders](/companies/twi/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/twi/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [402](/filings/0000899751-24-000091.md) | [390 d](/filings/0000899751-26-000007.md) | [482](/filings/0000899751-25-000039.md) | [532](/filings/0000899751-25-000070.md) | [448](/filings/0000899751-25-000087.md) | [384 d](/filings/0000899751-26-000007.md) | [491](/filings/0000899751-26-000041.md) | [461](/filings/0000899751-26-000063.md) | [466](/filings/0000899751-25-000087.md) | [410 d](/filings/0000899751-26-000007.md) | [505](/filings/0000899751-26-000041.md) | [485](/filings/0000899751-26-000063.md) | | Cost of revenue | $m | [336](/filings/0000899751-24-000091.md) | [332 d](/filings/0000899751-26-000007.md) | [405](/filings/0000899751-25-000039.md) | [452](/filings/0000899751-25-000070.md) | [389](/filings/0000899751-25-000087.md) | [342 d](/filings/0000899751-26-000007.md) | [422](/filings/0000899751-26-000041.md) | [392](/filings/0000899751-26-000063.md) | [396](/filings/0000899751-25-000087.md) | [366 d](/filings/0000899751-26-000007.md) | [434](/filings/0000899751-26-000041.md) | [410](/filings/0000899751-26-000063.md) | | Gross profit | $m | [66.1](/filings/0000899751-24-000091.md) | [58.3 d](/filings/0000899751-26-000007.md) | [77.4](/filings/0000899751-25-000039.md) | [80.4](/filings/0000899751-25-000070.md) | [58.8](/filings/0000899751-25-000087.md) | [41.2 d](/filings/0000899751-26-000007.md) | [68.6](/filings/0000899751-26-000041.md) | [69.3](/filings/0000899751-26-000063.md) | [70.9](/filings/0000899751-25-000087.md) | [44.7 d](/filings/0000899751-26-000007.md) | [71.4](/filings/0000899751-26-000041.md) | [74.9](/filings/0000899751-26-000063.md) | | Research and development | $m | [3.2](/filings/0000899751-24-000091.md) | [3.1 d](/filings/0000899751-26-000007.md) | [3.7](/filings/0000899751-25-000039.md) | [4.2](/filings/0000899751-25-000070.md) | [4.2](/filings/0000899751-25-000087.md) | [4.4 d](/filings/0000899751-26-000007.md) | [4.5](/filings/0000899751-26-000041.md) | [4.3](/filings/0000899751-26-000063.md) | [4.6](/filings/0000899751-25-000087.md) | [4.9 d](/filings/0000899751-26-000007.md) | [5.3](/filings/0000899751-26-000041.md) | [5.4](/filings/0000899751-26-000063.md) | | Selling, general and administrative | $m | [33.6](/filings/0000899751-24-000091.md) | [32.0 d](/filings/0000899751-26-000007.md) | [39.4](/filings/0000899751-25-000039.md) | [51.6](/filings/0000899751-25-000070.md) | [49.5](/filings/0000899751-25-000087.md) | [51.3 d](/filings/0000899751-26-000007.md) | [49.9](/filings/0000899751-26-000041.md) | [52.4](/filings/0000899751-26-000063.md) | [53.1](/filings/0000899751-25-000087.md) | [47.9 d](/filings/0000899751-26-000007.md) | [52.4](/filings/0000899751-26-000041.md) | [52.7](/filings/0000899751-26-000063.md) | | Operating income | $m | [27.0](/filings/0000899751-24-000091.md) | [20.7 d](/filings/0000899751-26-000007.md) | [25.1](/filings/0000899751-25-000039.md) | [22.3](/filings/0000899751-25-000070.md) | [2.8](/filings/0000899751-25-000087.md) | [(17.0) d](/filings/0000899751-26-000007.md) | [11.8](/filings/0000899751-26-000041.md) | [10.2](/filings/0000899751-26-000063.md) | [9.7](/filings/0000899751-25-000087.md) | [(10.9) d](/filings/0000899751-26-000007.md) | [(13.8)](/filings/0000899751-26-000041.md) | [13.3](/filings/0000899751-26-000063.md) | | Interest expense | $m | [7.2](/filings/0000899751-24-000091.md) | [(3.7) d](/filings/0000899751-24-000018.md) | [5.5](/filings/0000899751-24-000056.md) | [7.2](/filings/0000899751-24-000082.md) | [9.0](/filings/0000899751-24-000091.md) | [9.3 d](/filings/0000899751-26-000007.md) | [9.5](/filings/0000899751-26-000041.md) | [9.7](/filings/0000899751-26-000063.md) | [9.7](/filings/0000899751-25-000087.md) | [9.8 d](/filings/0000899751-26-000007.md) | [9.9](/filings/0000899751-26-000041.md) | [10.0](/filings/0000899751-26-000063.md) | | Income tax | $m | [4.7](/filings/0000899751-24-000091.md) | [(2.3) d](/filings/0000899751-26-000007.md) | [9.7](/filings/0000899751-25-000039.md) | [15.5](/filings/0000899751-25-000070.md) | [12.9](/filings/0000899751-25-000087.md) | [(26.2) d](/filings/0000899751-26-000007.md) | [4.2](/filings/0000899751-26-000041.md) | [4.7](/filings/0000899751-26-000063.md) | [1.1](/filings/0000899751-25-000087.md) | [39.9 d](/filings/0000899751-26-000007.md) | [4.6](/filings/0000899751-26-000041.md) | [(0.0)](/filings/0000899751-26-000063.md) | | Net income | $m | [19.3](/filings/0000899751-24-000091.md) | [(2.6) d](/filings/0000899751-26-000007.md) | [9.2](/filings/0000899751-25-000039.md) | [2.1](/filings/0000899751-25-000070.md) | [(18.2)](/filings/0000899751-25-000087.md) | [1.3 d](/filings/0000899751-26-000007.md) | [(0.6)](/filings/0000899751-26-000041.md) | [(4.5)](/filings/0000899751-26-000063.md) | [(2.3)](/filings/0000899751-25-000087.md) | [(56.0) d](/filings/0000899751-26-000007.md) | [(24.2)](/filings/0000899751-26-000041.md) | [5.8](/filings/0000899751-26-000063.md) | | Diluted EPS | $ per share | [0.31](/filings/0000899751-24-000091.md) | not reported | [0.14](/filings/0000899751-25-000039.md) | [0.03](/filings/0000899751-25-000070.md) | [(0.25)](/filings/0000899751-25-000087.md) | not reported | [(0.01)](/filings/0000899751-26-000041.md) | [(0.07)](/filings/0000899751-26-000063.md) | [(0.04)](/filings/0000899751-25-000087.md) | not reported | [(0.38)](/filings/0000899751-26-000041.md) | [0.09](/filings/0000899751-26-000063.md) | | Basic EPS | $ per share | [0.31](/filings/0000899751-24-000091.md) | not reported | [0.14](/filings/0000899751-25-000039.md) | [0.03](/filings/0000899751-25-000070.md) | [(0.25)](/filings/0000899751-25-000087.md) | not reported | [(0.01)](/filings/0000899751-26-000041.md) | [(0.07)](/filings/0000899751-26-000063.md) | [(0.04)](/filings/0000899751-25-000087.md) | not reported | [(0.38)](/filings/0000899751-26-000041.md) | [0.09](/filings/0000899751-26-000063.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | not reported | [220](/filings/0000899751-25-000009.md) | not reported | [224](/filings/0000899751-24-000082.md) | [227](/filings/0000899751-24-000091.md) | [196](/filings/0000899751-26-000007.md) | [174](/filings/0000899751-25-000039.md) | [185](/filings/0000899751-25-000070.md) | [205](/filings/0000899751-25-000087.md) | [203](/filings/0000899751-26-000063.md) | [171](/filings/0000899751-26-000041.md) | [180](/filings/0000899751-26-000063.md) | | Current assets | $m | [881](/filings/0000899751-23-000075.md) | [877](/filings/0000899751-25-000009.md) | [1,155](/filings/0000899751-24-000056.md) | [1,092](/filings/0000899751-24-000082.md) | [1,026](/filings/0000899751-24-000091.md) | [912](/filings/0000899751-26-000007.md) | [1,026](/filings/0000899751-25-000039.md) | [1,036](/filings/0000899751-25-000070.md) | [1,034](/filings/0000899751-25-000087.md) | [986](/filings/0000899751-26-000063.md) | [1,051](/filings/0000899751-26-000041.md) | [1,053](/filings/0000899751-26-000063.md) | | Total assets | $m | [1,258](/filings/0000899751-23-000075.md) | [1,289](/filings/0000899751-25-000009.md) | [1,814](/filings/0000899751-24-000056.md) | [1,734](/filings/0000899751-24-000082.md) | [1,687](/filings/0000899751-24-000091.md) | [1,585](/filings/0000899751-26-000007.md) | [1,722](/filings/0000899751-25-000039.md) | [1,752](/filings/0000899751-25-000070.md) | [1,750](/filings/0000899751-25-000087.md) | [1,673](/filings/0000899751-26-000063.md) | [1,715](/filings/0000899751-26-000041.md) | [1,722](/filings/0000899751-26-000063.md) | | Current liabilities | $m | [375](/filings/0000899751-23-000075.md) | [363](/filings/0000899751-25-000009.md) | [495](/filings/0000899751-24-000056.md) | [454](/filings/0000899751-24-000082.md) | [431](/filings/0000899751-24-000091.md) | [387](/filings/0000899751-26-000007.md) | [455](/filings/0000899751-25-000039.md) | [441](/filings/0000899751-25-000070.md) | [453](/filings/0000899751-25-000087.md) | [428](/filings/0000899751-26-000063.md) | [479](/filings/0000899751-26-000041.md) | [498](/filings/0000899751-26-000063.md) | | Total liabilities | $m | [825](/filings/0000899751-23-000075.md) | [822](/filings/0000899751-25-000009.md) | [1,183](/filings/0000899751-24-000056.md) | [1,120](/filings/0000899751-24-000082.md) | [1,089](/filings/0000899751-24-000091.md) | [1,091](/filings/0000899751-26-000007.md) | [1,183](/filings/0000899751-25-000039.md) | [1,175](/filings/0000899751-25-000070.md) | [1,176](/filings/0000899751-25-000087.md) | [1,151](/filings/0000899751-26-000063.md) | [1,213](/filings/0000899751-26-000041.md) | [1,212](/filings/0000899751-26-000063.md) | | Long-term debt | $m | not reported | [426](/filings/0000899751-24-000018.md) | not reported | [554](/filings/0000899751-24-000082.md) | [522](/filings/0000899751-24-000091.md) | [568](/filings/0000899751-25-000009.md) | [588](/filings/0000899751-25-000039.md) | [588](/filings/0000899751-25-000070.md) | [581](/filings/0000899751-25-000087.md) | [588](/filings/0000899751-26-000007.md) | [614](/filings/0000899751-26-000041.md) | [595](/filings/0000899751-26-000063.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [433](/filings/0000899751-23-000075.md) | [467](/filings/0000899751-25-000009.md) | [630](/filings/0000899751-24-000056.md) | [609](/filings/0000899751-24-000082.md) | [598](/filings/0000899751-24-000091.md) | [496](/filings/0000899751-26-000007.md) | [534](/filings/0000899751-25-000039.md) | [570](/filings/0000899751-25-000070.md) | [569](/filings/0000899751-25-000087.md) | [514](/filings/0000899751-26-000063.md) | [495](/filings/0000899751-26-000041.md) | [501](/filings/0000899751-26-000063.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebt - Current portion of debt: not reported - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [51.2 d](/filings/0000899751-24-000091.md) | [39.2 d](/filings/0000899751-26-000007.md) | [2.0](/filings/0000899751-25-000039.md) | [70.8 d](/filings/0000899751-25-000070.md) | [59.9 d](/filings/0000899751-25-000087.md) | [8.7 d](/filings/0000899751-26-000007.md) | [(38.6)](/filings/0000899751-26-000041.md) | [14.3 d](/filings/0000899751-26-000063.md) | [41.5 d](/filings/0000899751-25-000087.md) | [12.8 d](/filings/0000899751-26-000007.md) | [(46.5)](/filings/0000899751-26-000041.md) | [39.1 d](/filings/0000899751-26-000063.md) | | Capital expenditure | $m | [13.9 d](/filings/0000899751-24-000091.md) | [19.3 d](/filings/0000899751-26-000007.md) | [16.6](/filings/0000899751-25-000039.md) | [17.6 d](/filings/0000899751-25-000070.md) | [18.1 d](/filings/0000899751-25-000087.md) | [13.3 d](/filings/0000899751-26-000007.md) | [15.0](/filings/0000899751-26-000041.md) | [10.1 d](/filings/0000899751-26-000063.md) | [11.6 d](/filings/0000899751-25-000087.md) | [17.9 d](/filings/0000899751-26-000007.md) | [13.3](/filings/0000899751-26-000041.md) | [12.8 d](/filings/0000899751-26-000063.md) | | Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $m | [12.7 d](/filings/0000899751-24-000091.md) | [13.5 d](/filings/0000899751-24-000018.md) | [1.4](/filings/0000899751-25-000039.md) | [6.4 d](/filings/0000899751-25-000070.md) | [8.3 d](/filings/0000899751-25-000087.md) | not reported | [0.0](/filings/0000899751-25-000039.md) | [0.0 d](/filings/0000899751-25-000070.md) | [0.0 d](/filings/0000899751-25-000087.md) | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: not reported - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [63.2](/filings/0000899751-23-000075.md) | [63.6](/filings/0000899751-24-000056.md) | [63.2](/filings/0000899751-24-000082.md) | [63.1](/filings/0000899751-24-000091.md) | [65.7](/filings/0000899751-25-000039.md) | [73.1](/filings/0000899751-25-000070.md) | [72.0](/filings/0000899751-25-000087.md) | [63.3](/filings/0000899751-26-000041.md) | [63.7](/filings/0000899751-26-000063.md) | [63.9](/filings/0000899751-25-000087.md) | [64.1](/filings/0000899751-26-000041.md) | [64.5](/filings/0000899751-26-000063.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 64,542,352 at 2026-07-20, from the cover of the [10-Q filed 2026-07-30](/filings/0000899751-26-000063.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.